Skip to main content
. Author manuscript; available in PMC: 2013 Jul 2.
Published in final edited form as: Arthritis Rheum. 2011 May;63(5):1237–1245. doi: 10.1002/art.30164

Figure 5.

Figure 5

Methotrexate and anti-TNFα treatments do not correct the defective peripheral B cell tolerance checkpoint. Comparative frequencies of HEp-2 reactive and polyreactive clones before and after methotrexate or anti-TNFα treatment is depicted in (A) and (B) respectively. The frequencies of HEp-2 reactive (C) and polyreactive (D) B cells in healthy donors and RA patients before and after methotrexate and anti-TNFα treatment are shown. Each diamond is an individual and the average is represented with a bar. E, The percentages of ANA-expressing clones in mature naïve B cells from healthy donors, untreated RA patients and patients after either treatment are shown. Standard deviations are indicated.